Yuka Hayashi is a reporter at The Wall Street Journal. She covers global trade, China-US relations, economic policies, and international relations, with a keen focus on the intersection of these topics and technology. Yuka's work has been featured in prominent publications including MarketWatch, Barron's, La Tercera, Financial News, Ya Libnan, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Yuka Hayashi's coverage heavily focuses on global trade, China-US relations, economic policies, international relations, and technology. She often covers government announcements and legal policy regulation related to these topics.
Given her focus on politics, finance & economy, and international relations with a national (United States) geographic focus, Yuka would likely be interested in pitches providing insights into the impact of global trade developments or US economic policies on specific industries or businesses. Moreover, as she frequently cites data in her articles suggesting a reliance on factual information for reporting stories accurately.
Pitches should offer expert analysis from professionals who can provide valuable perspectives regarding the implications of changing regulations and geopolitical events on various sectors such as technology or auto industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Yuka Hayashi, Kazuto Tajiri, Aiko Murayama, Ichiro Yasuda, Nozomu Muraishi, Eiki Ishizaka
Background/Objectives: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC), but its anti-tumor efficacy remains limited.
